Skip to main content
. Author manuscript; available in PMC: 2015 Dec 16.
Published in final edited form as: Curr Opin Immunol. 2015 Aug 1;35:137–143. doi: 10.1016/j.coi.2015.06.010

Figure 2.

Figure 2

Summary of two HCV vaccines that advanced to human clinical trials. Very different approaches to vaccine antigen selection and delivery reflect uncertainty about mechanisms of protective immunity against HCV. The Chiron vaccine is comprised of adjuvanted recombinant envelope glycoproteins E1 and E2. The Okairos vaccine is comprised of recombinant viruses expressing the non-structural 3 to 5 genes as indicated in the figure.